Anixa Advances Ovarian Cancer CAR-T With Higher Dosing

An announcement from Anixa Biosciences ( (ANIX) ) is now available.

On February 9, 2026, Anixa Biosciences reported updated data from its ongoing Phase 1 trial of its ovarian cancer CAR-T therapy, lira-cel, in women with recurrent disease who have exhausted standard therapies. Among 12 patients treated at relatively low dose levels, seven lived beyond the typical median survival of three to four months, with one patient surviving 28 months and several others living more than a year.

The trial has shown a clean safety profile with no dose-limiting toxicities, enabling regulators to approve a major protocol amendment that raises potential dosing up to 1×10⁹ cells/kg and introduces lymphodepletion to potentially boost efficacy. The move significantly expands the scope of the early-stage program, reflects growing confidence in intra-peritoneal CAR-T delivery for solid tumors, and could strengthen Anixa’s position in the competitive cancer cell-therapy field if higher doses and the new regimen continue to demonstrate safety and signs of benefit.

The most recent analyst rating on (ANIX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Anixa Biosciences stock, see the ANIX Stock Forecast page.

Spark’s Take on ANIX Stock

According to Spark, TipRanks’ AI Analyst, ANIX is a Neutral.

Anixa Biosciences faces significant financial challenges, primarily due to its inability to generate revenue and persistent losses, which are compounded by negative cash flows. While its technical indicators show some positive momentum, the negative P/E ratio and lack of dividends make valuation unattractive. The company’s financial performance is the primary concern, overshadowing technical and valuation aspects.

To see Spark’s full report on ANIX stock, click here.

More about Anixa Biosciences

Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Its therapeutic portfolio includes lira-cel, an ovarian cancer immunotherapy developed with Moffitt Cancer Center using CER-T cell technology, and a suite of cancer vaccines co-developed with Cleveland Clinic targeting “retired” proteins in breast, ovarian, lung, colon, and prostate cancers.

The company operates through partnerships with major research institutions, licensing vaccine technologies and collaborating on next-generation immunotherapies. This model allows Anixa to access and develop emerging oncology platforms while sharing commercialization economics such as royalties with its academic partners.

Average Trading Volume: 315,942

Technical Sentiment Signal: Strong Sell

Current Market Cap: $98.8M

For a thorough assessment of ANIX stock, go to TipRanks’ Stock Analysis page.